All In Biotech

NDA 022395 · Averitas

Qutenza

Capsaicin · Topical

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Nov 16, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

185

31 Phase 3, 12 recruiting

FAERS reports

3,257

1,865 serious, 156 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2026.

QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. QUTENZA is a TRPV1 channel agonist indicated for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. ( 1 )

Mechanism: Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. This is followed by pain relief thought to be mediated by a reduction in TRPV1-expressing nociceptive nerve endings [see Clinical Pharmacology ( 12.2 )] . Over the course of several months, there may be a gradual re-emergence of painful neuropathy...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • QUTENZA · CAPSAICIN 8% · PATCH, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Capsaicin" as an intervention, any sponsor and status, largest first.

All 185 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • application site pain607
  • pain424
  • drug ineffective377
  • burning sensation330
  • pain in extremity215
  • application site erythema165
  • fatigue159
  • off label use145
  • insomnia110
  • dyspnoea105
  • paraesthesia100
  • weight increased100

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200416
200524
200621
200723
20086
200913
201017
201144
201286
201378
2014117
2015105
2016133
2017114
2018137
2019173
2020130
2021183
2022197
2023250
2024326
2025724
2026340

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qutenza (Capsaicin/Skin Cleanser)

2024 spending

$21.3M

Beneficiaries

3,782

6,290 claims

Per beneficiary

$5,645

$3,018.61 per unit

View as table
YearSpending
2020$730,180
2021$1,979,006
2022$4,952,531
2023$12,460,288
2024$21,347,581

Part B: Qutenza (Capsaicin/Skin Cleanser) · HCPCS J7336

2024 spending

$29.5M

Beneficiaries

5,271

9,155 claims

Per beneficiary

$5,603

2024 ASP limit $3.31 per unit

View as table
YearSpending
2020$238,861
2021$2,275,396
2022$11,137,495
2023$22,106,184
2024$29,534,286

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 944 on PubMed

Sponsor: Averitas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.